BioCentury
ARTICLE | Finance

First mover money

GamaMabs attracts EUR 3M based on first-in-class mAb for ovarian cancer

October 14, 2013 7:00 AM UTC

A group of French VCs are throwing their hat in the cancer stem cell ring, providing €3.1 million ($4.2 million) to GamaMabs Pharma S.A. to develop a preclinical mAb against a novel ovarian cancer target.

GamaMabs debuted last week as a spinout from hematology and immunology company LFB S.A., which took an undisclosed minority stake in exchange for exclusive rights to 3C23K. The humanized mAb targets anti-Mullerian hormone receptor type II (AMHR2)...